Biotech Values

[jq1234]

Did you read the article?

Viekira will help fill that gap before it appears. Its sales are estimated to total $2.6 billion this year versus next to nothing last year, and to peak at $3.4 billion next year before sliding back to $2.6 billion by 2019. Those are obviously estimates subject to change, but the big picture is promising. JPMorgan in a Thursday note wrote that despite Gilead’s discounting, it’s confident that AbbVie has a multibillion dollar hep-C business.